Search clinical trials for: BMS-986178

Total 3151 results

Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Healthy Participants

United States
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF)

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Obese But Otherwise Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Cedars-Sinai Medical Center
Bristol-Myers Squibb

Terminated

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Urogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, Male

United States
Mackay Memorial Hospital

Unknown

Stent Placement and the Risk of New-onset AF in Patients With AMI

Acute Myocardial Infarction | Atrial Fibrillation New Onset
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Hepatitis C

United States
Bristol-Myers Squibb
Exelixis

Completed

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Basal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)

United States, Canada
Bristol-Myers Squibb

Completed

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan

Neoplasms

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid Tumor

United States
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Celgene

Active, not recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

United States, Canada, Denmark, Australia, Belgium, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Completed

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Cancer

United States, France
Bristol-Myers Squibb

Completed

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Autoimmune Diseases | Inflammatory Diseases

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Not yet recruiting

Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success? (OUTBACK)

Osteochondral Lesion of Talus
Bristol-Myers Squibb

Completed

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Atherosclerosis

United States
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Advanced Cancer

United States, Spain, France, Austria, Italy, Australia, Canada, Switzerland
Bluedrop Medical Limited

Recruiting

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration (MASTER)

Diabetic Foot

United States
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Taiwan, Japan, Brazil, Colombia, Germany, Poland, Puerto Rico, China, Mexico, Argentina, France, Chile, Australia, India, Spain, United Kingdom, Romania, Ireland
R-Pharm

Completed

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of, Taiwan, Japan, Singapore, Hong Kong
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Terminated

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Canada, Denmark, France, Finland
Bristol-Myers Squibb

Terminated

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Non Small Cell Lung Cancer

United States
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Recruiting

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

Parkinson Disease

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

United States, Australia, Canada, France, Germany, Ireland, Italy, Spain, United Kingdom
Bristol-Myers Squibb

Terminated

Multiple Ascending Dose of BMS-911543

Cancer

United States, Australia
Bristol-Myers Squibb
This trial was conducted previously by Cormorant

Completed

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Solid Tumor

United States
InspireMD

Terminated

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction (MASTER-II)

ST Elevation Myocardial Infarction

United States, Poland, France, Spain, United Kingdom, Finland, Netherlands, Israel, Czech Republic, Germany, Belgium, Estonia
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Alzheimer's Disease
Bristol-Myers Squibb

Terminated

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Lupus Nephritis

United States, Taiwan, Spain, United Kingdom, Netherlands, Germany, China, Australia, Belgium, Mexico, Korea, Republic of, Czechia, Russian Federation, Israel, Canada, Italy
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
R-Pharm

Completed

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

Solid Tumors
Bristol-Myers Squibb

Completed

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Soft Tissue Sarcoma | Transitional Cell Carcinoma | Advanced Non-small Cell Lung Cancer | Gastric/Esophageal Adenocarcinoma | Pancreatic Cancer Including Ampulla of Vater

United States, Argentina, Germany, Belgium, Canada, Poland, Netherlands, United Kingdom, France
Bristol-Myers Squibb

Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Neoplasms | Solid Tumors | Metastases

Australia
Bristol-Myers Squibb

Completed

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Withdrawn

Japanese Phase 1 Study of BMS-844203 (CT322)

Neoplasms

Japan
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Prostate Cancer

Japan

Search clinical trials for: BMS-986178

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations